摘要
[目的]探讨肺癌并上腔静脉综合征(superior vena cava syndrome,SVCS)患者血浆D-二聚体、血清CEA、CYFRA21-1水平变化及意义。[方法 ]60例肺癌合并SVCS的Ⅲ、Ⅳ期患者为实验组,60例未合并SVCS的Ⅲ、Ⅳ期患者作为对照组。给予两组患者三维适形放疗联合化疗治疗,检测血D-二聚体水平、血清CEA及CYFRA21-1水平。[结果]实验组患者治疗后的血D-二聚体、CEA、CYFRA21-1水平均显著低于治疗前(P<0.05),差异有统计学意义,与对照组比较无显著差异;治疗前实验组患者的D-二聚体、CEA、CYFRA21-1水平均显著高于对照组(P<0.05)。实验组缓解患者的D-二聚体、CEA、CYFRA21-1水平均显著低于未缓解患者(P<0.05)。[结论]肺癌并SVCS患者血液中具有较高的D-二聚体、CEA、CYFRA21-1水平,三维适形放疗联合化疗治疗能够有效降低其水平,改善患者预后。
[Purpose] To investigate the changes and significances of level of D-dimer in plasma and serum levels of carcinoembryonic antigen（CEA）and cytokeratin 19 fragment 21-1（CYFRA21-1）in patients with lung cancer complicated with superior vena cava syndrome（SVCS）. [Methods]All 120 patients with lung cancer stage Ⅲ/Ⅳ were recruited in the study. Sixty cases with SVCS as the experimental group,and 60 cases without SCVS as control group received three-dimensional conformal radiation therapy combined with chemotherapy. The level of D-dimer in plasma and serum levels of CEA,CYFRA21-1 were detected in all patients. [Results] The levels of D-dimer,CEA and CYFRA21-1 in the experimental group after treatment were significantly lower than those before treatment（P 0.05）,but no significant difference were found compared with control group. While before treatment,the levels of D-dimer,CEA and CYFRA21-1 in the experimental group were significantly higher than those in control group（P0.05）.In the experimental group,the levels of D-dimer,CEA and CYFRA21-1 in patients with CR ＋PR were significantly lower than those in patients with SD ＋PD（P 0.05）. [Conclusion] Lung cancer patients complicated with SVCS have high levels of D-dimer,CEA and CYFRA21-1 in blood. Three-dimensional conformal radiation therapy combined with chemotherapy might effectively reduce their levels and improve patients＇ prognosis.
出处
《肿瘤学杂志》
CAS
2016年第3期218-221,共4页
Journal of Chinese Oncology
关键词
肺肿瘤
上腔静脉综合征
D-二聚体
癌胚抗原
CYFRA21-1
lung neoplasms
superior vena cava syndrome （SVCS）
D-dimer
carcinoembryonic antigen（CEA）
cytokeratin 19 fragment 21-1（CYFRA21-1）
